Vimizim

(elosulfase alfa)
5 ML elosulfase alfa 1 MG/ML Injection [Vimizim]

Dosage & administration

2 mg per kg body weight administered once every week as an intravenous infusion over a minimum of 3.5 to 4.5 hours, based on infusion volume .

drug label

Vimizim prescribing information

Have more Vimizim questions?

Submit MSL Request
Learn More

Need to report a Vimizim issue?

ONLINE FORM
Report adverse event
Learn More

prior authorization

Vimizim Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRAND
Coverage Authorization Request
Coverage Authorization Appeals
Coverage Authorization Guide
Learn More

Benefits investigation

BioMarin RareConnections Patient Authorization Form - To be used along with comprehensive support program application
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Vimizim Financial assistance options

Co-pay savings program

commercial only

NOT PROVIDED BY BRAND
Enroll in Patient Savings Program
Learn More

Bridge program

commercial only
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Learn More

patient education

Vimizim Patient education

Getting started on Vimizim

NOT PROVIDED BY BRAND
Instructions For Use - Morquio A

Patient toolkit

About Vimizim
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Vimizim FAQs

FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.